Analyst Price Target is $3.00
▲ +233.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Matinas BioPharma in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 233.33% upside from the last price of $0.90.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Matinas BioPharma. This Buy consensus rating has held steady for over two years.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.